Squarepoint
CMPX icon

Squarepoint’s Compass Therapeutics CMPX Stock Holding History

Squarepoint’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Buy
1,007,507
+957,305
+1,907% +$2.83M ﹤0.01% 2263
2026
Q1 		$266K Sell
50,202
-75,990
-60% -$439K ﹤0.01% 3800
2025
Q4 		$678K Buy
126,192
+38,339
+44% +$177K ﹤0.01% 2950
2025
Q3 		$307K Buy
87,853
+67,080
+323% +$212K ﹤0.01% 3645
2025
Q2 		$54K Buy
+20,773
New +$42.8K ﹤0.01% 4291
2025
Q1 		– Sell
-24,072
Closed -$34.9K – 4688
2024
Q4 		$34.9K Buy
+24,072
New +$40K ﹤0.01% 4898
2024
Q3 		– Sell
-64,133
Closed -$64.1K – 4173
2024
Q2 		$64.1K Buy
64,133
+13,321
+26% +$19.5K ﹤0.01% 3875
2024
Q1 		$101K Sell
50,812
-37,908
-43% -$65.5K ﹤0.01% 3798
2023
Q4 		$138K Buy
+88,720
New +$154K ﹤0.01% 3695
2023
Q2 		– Sell
-16,263
Closed -$53.2K – 3618
2023
Q1 		$53.2K Buy
+16,263
New +$63.9K ﹤0.01% 3047

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Squarepoint's CMPX Position: Q2 2026 in Review

Squarepoint increased its Compass Therapeutics (CMPX) stake by 1,907% in Q2 2026, buying an estimated $2.83M and bringing the position to 1,007,507 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2263.

Squarepoint first reported a position in CMPX in Q1 2023 and has held it in 10 quarters since. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Squarepoint held 1,007,507 shares of Compass Therapeutics worth $2.21M as of Q2 2026.
  • Squarepoint bought 957,305 Compass Therapeutics shares in Q2 2026, an estimated $2.83M.
  • Compass Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2263 holding.
  • Squarepoint first reported a position in Compass Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.